Mizuho Securities Reaffirms Their Buy Rating on Selecta Biosciences (SELB)


Mizuho Securities analyst Difei Yang maintained a Buy rating on Selecta Biosciences (SELB) today and set a price target of $4. The company’s shares closed yesterday at $2.40, close to its 52-week low of $1.41.

Yang observed:

“We believe these readouts will be key drivers for SELB shares in late 2019/early 2020.”

According to TipRanks.com, Yang is a 5-star analyst with an average return of 12.1% and a 43.9% success rate. Yang covers the Healthcare sector, focusing on stocks such as Nightstar Therapeutics Limited, Xeris Pharmaceuticals Inc, and Alder Biopharmaceuticals.

Selecta Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $8, implying a 233.3% upside from current levels. In a report released yesterday, Stifel Nicolaus also reiterated a Buy rating on the stock with a $7 price target.

See today’s analyst top recommended stocks >>

The company has a one-year high of $16.55 and a one-year low of $1.41. Currently, Selecta Biosciences has an average volume of 521.2K.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Selecta Biosciences, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of nanoparticle immunomodulatory drugs for the treatment and prevention of human diseases. it produces the Synthetic Vaccine Particles (SVP) platform for immune tolerance and immune stimulation.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts